Home › Compare › LEJUY vs ABBV
LEJUY yields 39215.69% · ABBV yields 3.06%● Live data
📍 LEJUY pulled ahead of the other in Year 1
Combined, LEJUY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LEJUY + ABBV for your $10,000?
Leju Holdings Limited, through its subsidiaries, provides online to offline (O2O) real estate services in the People's Republic of China. The company offers real estate e-commerce and online advertising services through its online platform, various mobile applications, and Weixin mini programs. Its O2O services for new residential properties include selling discount coupons; facilitating online property viewing, physical property visits, marketing events, and pre-sale customer support; and issuing commission coupons, as well as provides information platform to individual brokers. The company also provides advertisement placement services to advertisers, primarily property developers through online cross-media and cross-platform product portfolio; and brand promotion services to advertisers, including real estate developers and home furnishing suppliers. In addition, it offers Leju Finance, an online platform that provides information and news on the real estate industry, market, and developers featuring their financial performances. The company was incorporated in 2013 and is headquartered in Beijing, the People's Republic of China. Leju Holdings Limited operates as a subsidiary of E-House (China) Enterprise Holdings Limited.
Full LEJUY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.